SCHEMBL3021640

SCHEMBL3021640

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.36
TSHR P16473 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 3/20 0.35
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM2B Q8NHM5 1/20 0.35
RECQL P46063 1/20 0.35
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR1 P21554 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012479 0.94 MAPT (0.39) ACHETSHRNPSR1HTTKMT2A
SCHEMBL3004810 0.93 TSHR (0.35) ACHETSHRNPSR1HTTMEN1
SCHEMBL2998446 0.93 GAA (0.36) MAPTGAASMN1; SMN2KDM2BTP53
SCHEMBL3011591 0.93 ACHE (0.36) ACHETSHRNPSR1HTTMEN1
SCHEMBL3011255 0.91 MAPT (0.37) TSHRNPSR1HTTKMT2AALDH1A1
SCHEMBL3022234 0.91 RECQL (0.39) TSHRMEN1KMT2APOLBALDH1A1
SCHEMBL3006085 0.91 GAA (0.38) ACHETSHRNPSR1HTTMEN1
SCHEMBL3004540 0.90 CNR2 (0.40) TSHRNPSR1MEN1KMT2APOLB
SCHEMBL2999661 0.90 MAPT (0.40) TSHRMEN1KMT2APOLBALDH1A1
SCHEMBL3018358 0.89 HTT (0.39) TSHRHTTPOLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ACHE 2411/4885TSHR 3320/4885NPSR1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.